Selank Mechanism of Action

Introduction

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide tuftsin analog characterized in preclinical and limited clinical research across several intersecting pharmacological mechanisms. Published investigations have identified three principal pathways through which Selank produces measurable biological effects in model systems: inhibition of enkephalin-degrading enzymes (enkephalinases), modulation of GABAergic neurotransmission at a gene-expression level, and regulation of brain-derived neurotrophic factor (BDNF) expression. The compound also demonstrates immunomodulatory activity through effects on cytokine gene expression. These pathways are not mutually exclusive and may interact at the level of interneuron circuits. Readers seeking background on the compound's chemistry and regulatory classification should refer to the Selank research overview.

Enkephalinase Inhibition: A Central Mechanistic Axis

Research published in Eksperimental'naia i Klinicheskaia Farmakologiia in 2001 identified enkephalinase inhibition as a candidate primary mechanism for Selank's pharmacological activity in behavioral models [1]. The study reported that Selank inhibited the enzymatic hydrolysis of plasma enkephalin in a concentration-dependent manner, with reported inhibitory potency exceeding that of reference peptidase inhibitors bacitracin and puromycin in that in vitro assay system. The authors proposed that prolonged enkephalin availability — through reduced enzymatic degradation — could represent a mechanistic basis for behavioral effects observed in anxiety models.

The physiological relevance of this mechanism is grounded in the established relationship between enkephalins and GABAergic interneuron regulation. Enkephalins act on mu and delta opioid receptors expressed on interneurons that modulate GABAergic output. Reduced enkephalin degradation would be expected to extend opioid receptor occupancy by endogenous ligands, altering inhibitory tone in relevant circuits. This downstream connectivity was proposed rather than directly demonstrated in the 2001 study, and the pathway has continued to motivate subsequent mechanistic investigation [1].

A 2012 study in the Journal of Evolutionary Biochemistry and Physiology by Narkevich and colleagues reported that Selank administration produced lasting alterations in carboxypeptidase H and related enzyme activities in rat nervous tissue, with effects persisting for 24 hours post-administration [2]. The authors proposed that altered carboxypeptidase activity could modulate neuropeptide processing more broadly than enkephalin catabolism alone — extending the mechanistic picture beyond a single enzyme target.

GABAergic Gene Expression Modulation

Although Selank does not share a binding pharmacophore with classical GABA-A receptor modulators such as benzodiazepines, published research has characterized its influence on GABAergic neurotransmission at the transcriptional level.

A 2016 study in Frontiers in Pharmacology by Volkova and colleagues assessed the expression of genes involved in GABAergic neurotransmission in rat brain tissue following Selank administration using quantitative PCR [3]. The authors reported altered expression of multiple GABAergic pathway genes — including genes encoding GABA-A receptor subunits and GABA transporter proteins — in rat cortex following acute administration. These findings were interpreted as consistent with an indirect influence on GABAergic neurotransmission, potentially mediated through the enkephalinase pathway described above rather than through direct receptor binding.

A companion investigation published in Frontiers in Pharmacology in 2017 by Filatova and colleagues examined Selank alongside GABA and the antipsychotic olanzapine in IMR-32 human neuroblastoma cells using an 84-gene GABAergic expression panel [4]. In that monoculture system, Selank did not produce statistically significant changes in gene expression. The authors proposed that the in vivo effects observed in rat cortex may depend on intact neural circuit activity or cell-type context absent in the monoculture system — an interpretation that positions the in vitro null finding as a methodological boundary condition rather than a contradiction of the in vivo data.

A 2017 study in Behavioural Neurology by Kasian and colleagues examined the interaction between Selank and diazepam in rats subjected to unpredictable chronic mild stress, using the elevated plus maze [5]. Combined Selank-diazepam administration produced anxiety indicator values approaching pre-stress baseline, whereas either compound alone produced incomplete normalization. The authors characterized this pattern as additive and noted that the mechanistic basis of the interaction — whether through convergent or complementary pathways — remained an active area of investigation [5].

BDNF Regulation in Preclinical Models

Multiple publications have examined Selank's reported effects on brain-derived neurotrophic factor (BDNF), a neurotrophin involved in synaptic plasticity and hippocampal-dependent learning in rodent systems.

A 2008 publication in Doklady Biological Sciences by Semenova and colleagues reported that intranasal Selank administration in rats was associated with altered BDNF mRNA levels in the hippocampus at three hours and altered BDNF protein levels at 24 hours post-administration, at both concentrations tested [6]. The anatomical distribution of observed changes led the authors to propose peptide-stimulated neurotrophin expression in hippocampal cells, distinct from altered axonal transport from remote brain regions.

A 2019 study in the Bulletin of Experimental Biology and Medicine by Laukova and colleagues extended this line of investigation to a chronic ethanol exposure model in rats [7]. Selank-treated ethanol-exposed animals showed altered BDNF content in both the hippocampus and prefrontal cortex compared to ethanol-exposed controls, in a pattern that differed directionally from the ethanol-alone group. These findings were interpreted as consistent with neurotrophin-mediated contributions to the compound's effects in the alcohol-exposure model.

A 2014 cDNA microarray investigation by Dolotov and colleagues identified altered expression of more than 36 hippocampal genes — predominantly encoding plasma membrane and ion-transport proteins — following acute Selank administration in rats [8]. Repeated administration produced changes in 20 genes. The transcriptomic breadth of these findings has informed subsequent efforts to map the molecular landscape through which Selank exerts its characterized effects.

Areas of Ongoing Investigation

The mechanistic profile of Selank presents several active research questions. Direct receptor binding data — including radioligand displacement studies at defined GABA-A subunit combinations or opioid receptor subtypes — have not been published in accessible English-language literature, making precise molecular target characterization an open area of inquiry. The mechanistic relationship among enkephalinase inhibition, GABAergic gene modulation, and BDNF regulation has not yet been mapped at a pathway level in a single integrated study. The basis of the reported Selank-diazepam additive interaction in the chronic stress model [5] similarly remains under investigation. Analogous mechanistic questions characterize the closely related compound Semax, another Russian neuropeptide whose GABAergic and neurotrophin interactions have been investigated in parallel with Selank.

A substantial portion of the overall mechanistic characterization of Selank exists in Russian-language publications not fully indexed in PubMed, representing an additional area where English-language literature review is ongoing. These open questions reflect the breadth of the research program rather than a ceiling on it.

References

1. Semenova TP, Kozlovskaya MM, Zakharova NM. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Eksperimental'naia i Klinicheskaia Farmakologiia. 2001;64(2):3–6. PMID: 11550013. https://pubmed.ncbi.nlm.nih.gov/11550013/

2. Narkevich VB, Klodt PM, Kudrin VS, Volkova AB, Kolomin TA, Andreeva LA, Myasoedov NF, Raevsky KS. Effect of selank on the main carboxypeptidases in the rat nervous tissue. Journal of Evolutionary Biochemistry and Physiology. 2012;48(3):302–308. https://doi.org/10.1134/S0022093012030073 PMID: 22827026.

3. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology. 2016;7:31. https://doi.org/10.3389/fphar.2016.00031 PMC4757669.

4. Filatova EV, Kasian AM, Kolomin TA, Rybalkina EY, Alieva AK, Andreeva LA, Limborska SA, Myasoedov NF, Pavlova GV, Slominsky PA, Shadrina MI. GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Frontiers in Pharmacology. 2017;8:89. https://doi.org/10.3389/fphar.2017.00089 PMID: 28293190. PMC5328971.

5. Kasian AM, Kolomin TA, Andreeva LA, Bondarenko ON, Myasoedov NF, Slominsky PA, Shadrina MI. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology. 2017;2017:5091027. https://doi.org/10.1155/2017/5091027 PMC5322660.

6. Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskiy II. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241–243. https://doi.org/10.1134/S0012496608040066

7. Laukova M, Alaluf LG, Serova LI, Arango V, Sabban EL. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex in rats. Bulletin of Experimental Biology and Medicine. 2019;167(5):641–644. https://doi.org/10.1007/s10517-019-04588-9

8. Dolotov OV, Sebentsova EA, Sourina MM, Malygina TR, Serebriakova EV, Andreeva LA, Alfeeva LYu, Grivennikov IA, Myasoedov NF. Changes in the transcription profile of the hippocampus in response to administration of the tuftsin analog Selank. Neuroscience and Behavioral Physiology. 2014;44(8):852–861. https://doi.org/10.1007/s11055-014-9992-4 PMID: 24450168.